ZA202202863B - Compounds suitable for the treatment and prophylaxis of muscle wasting and other conditions - Google Patents
Compounds suitable for the treatment and prophylaxis of muscle wasting and other conditionsInfo
- Publication number
- ZA202202863B ZA202202863B ZA2022/02863A ZA202202863A ZA202202863B ZA 202202863 B ZA202202863 B ZA 202202863B ZA 2022/02863 A ZA2022/02863 A ZA 2022/02863A ZA 202202863 A ZA202202863 A ZA 202202863A ZA 202202863 B ZA202202863 B ZA 202202863B
- Authority
- ZA
- South Africa
- Prior art keywords
- conditions
- prophylaxis
- treatment
- formula
- muscle wasting
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 206010028289 Muscle atrophy Diseases 0.000 title abstract 3
- 201000000585 muscular atrophy Diseases 0.000 title abstract 3
- 238000011321 prophylaxis Methods 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title abstract 2
- 208000021642 Muscular disease Diseases 0.000 abstract 1
- 201000009623 Myopathy Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 210000003205 muscle Anatomy 0.000 abstract 1
- 230000020763 muscle atrophy Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
- C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
- C07D311/18—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted otherwise than in position 3 or 7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19192107 | 2019-08-16 | ||
| PCT/EP2020/072911 WO2021032643A1 (en) | 2019-08-16 | 2020-08-14 | Compounds suitable for the treatment and prophylaxis of muscle wasting and other conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202202863B true ZA202202863B (en) | 2023-10-25 |
Family
ID=67659191
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2022/02863A ZA202202863B (en) | 2019-08-16 | 2022-03-09 | Compounds suitable for the treatment and prophylaxis of muscle wasting and other conditions |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12331042B2 (enExample) |
| EP (1) | EP4013497B1 (enExample) |
| JP (1) | JP2022544803A (enExample) |
| KR (1) | KR20220047807A (enExample) |
| CN (1) | CN114302881B (enExample) |
| AU (1) | AU2020334194A1 (enExample) |
| BR (1) | BR112022002769A2 (enExample) |
| CA (1) | CA3144700A1 (enExample) |
| CL (1) | CL2022000320A1 (enExample) |
| IL (1) | IL290540A (enExample) |
| MX (1) | MX2022002022A (enExample) |
| WO (1) | WO2021032643A1 (enExample) |
| ZA (1) | ZA202202863B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102823820B1 (ko) * | 2022-09-01 | 2025-06-23 | 단국대학교 천안캠퍼스 산학협력단 | 퓨로크로멘온계 화합물을 유효성분으로 포함하는 근감소증 예방 또는 치료용 약학 조성물 |
| WO2024068809A1 (en) * | 2022-09-30 | 2024-04-04 | Société des Produits Nestlé S.A. | Composition and method for treating muscle decline associated with renal disease or dysfunction |
| KR102995500B1 (ko) * | 2024-11-07 | 2026-07-23 | 아주대학교산학협력단 | 근감소증의 예방 또는 치료용 약학적 조성물 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA200803016B (en) * | 2005-09-29 | 2009-10-28 | Elan Pharmaceuticals Inc Wyeth | Carbamate compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| EP2072528A1 (en) | 2007-12-19 | 2009-06-24 | Labeit, Mr. Siegfried | A host cell deficient for MuRF1 and MuRF2 |
| US20140161729A1 (en) * | 2011-04-07 | 2014-06-12 | Cornell University | Cofluorons and methods of making and using them |
| CN106822153B (zh) * | 2011-06-06 | 2019-12-17 | 爱荷华大学研究基金会 | 用于抑制肌萎缩的方法 |
| AU2014290368B2 (en) * | 2013-07-18 | 2019-07-11 | Baylor College Of Medicine | Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia |
| WO2015050984A1 (en) * | 2013-10-01 | 2015-04-09 | New York University | Amino, amido, and heterocyclic compounds as modulators of rage activity and uses thereof |
| CN112274183A (zh) * | 2020-11-02 | 2021-01-29 | 李云莹 | 一种神经内科用脑部超声波治疗装置 |
-
2020
- 2020-08-14 CN CN202080057706.5A patent/CN114302881B/zh active Active
- 2020-08-14 EP EP20764952.6A patent/EP4013497B1/en active Active
- 2020-08-14 CA CA3144700A patent/CA3144700A1/en active Pending
- 2020-08-14 US US17/634,174 patent/US12331042B2/en active Active
- 2020-08-14 BR BR112022002769A patent/BR112022002769A2/pt not_active Application Discontinuation
- 2020-08-14 WO PCT/EP2020/072911 patent/WO2021032643A1/en not_active Ceased
- 2020-08-14 AU AU2020334194A patent/AU2020334194A1/en not_active Abandoned
- 2020-08-14 MX MX2022002022A patent/MX2022002022A/es unknown
- 2020-08-14 JP JP2022510087A patent/JP2022544803A/ja active Pending
- 2020-08-14 KR KR1020227007940A patent/KR20220047807A/ko not_active Ceased
-
2022
- 2022-02-08 CL CL2022000320A patent/CL2022000320A1/es unknown
- 2022-02-10 IL IL290540A patent/IL290540A/en unknown
- 2022-03-09 ZA ZA2022/02863A patent/ZA202202863B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2022002022A (es) | 2022-05-11 |
| EP4013497A1 (en) | 2022-06-22 |
| JP2022544803A (ja) | 2022-10-21 |
| WO2021032643A1 (en) | 2021-02-25 |
| AU2020334194A1 (en) | 2022-02-24 |
| CA3144700A1 (en) | 2021-02-25 |
| US12331042B2 (en) | 2025-06-17 |
| CN114302881A (zh) | 2022-04-08 |
| KR20220047807A (ko) | 2022-04-19 |
| EP4013497C0 (en) | 2023-10-04 |
| BR112022002769A2 (pt) | 2022-05-10 |
| US20220324852A1 (en) | 2022-10-13 |
| EP4013497B1 (en) | 2023-10-04 |
| IL290540A (en) | 2022-04-01 |
| CL2022000320A1 (es) | 2023-02-03 |
| CN114302881B (zh) | 2025-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202200519B (en) | Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents | |
| ZA202310378B (en) | Complement factor b inhibitor, and pharmaceutical composition thereof, preparation method therefor and use thereof | |
| CR20230310A (es) | Inhibidores de prmt5 | |
| MX2023009222A (es) | Inhibidores tricíclicos-amido-bicíclicos de prmt5. | |
| CR20210563A (es) | Compuestos y métodos para el tratamiento de covid-19 | |
| WO2021147236A9 (zh) | 取代氨基丙酸酯类化合物在治疗SARS-CoV-2感染中的应用 | |
| EP4360707A3 (en) | Compositions for treating spinal muscular atrophy | |
| MX2022004450A (es) | Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1. | |
| WO2019143902A3 (en) | Substituted heterocycles as antiviral agents | |
| MX2025008327A (es) | Composiciones y metodos para el tratamiento de trastornos del snc | |
| NZ739026A (en) | 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
| PH12021552930A1 (en) | 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
| EP4252848A3 (en) | Oxysterols and methods of use thereof | |
| PH12022551523A1 (en) | Cyclic compounds and methods of using same | |
| PH12022550876A1 (en) | Heteroaryl-biphenyl amides for the treatment of pd-l1 diseases | |
| PH12020551117A1 (en) | Compositions for preventing or treating uveitis | |
| CL2022000320A1 (es) | Compuestos adecuados para el tratamiento y la profilaxis del desgaste muscular y otras afecciones | |
| MY202753A (en) | Griseofulvin compound and pharmaceutical use thereof | |
| PH12021552004A1 (en) | Heterocyclic compound, pharmaceutical composition comprising same, preparation method therefor, and use thereof | |
| PH12019500618A1 (en) | Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease | |
| PH12020552186A1 (en) | Cyanotriazole compounds and uses thereof | |
| MX2025012370A (es) | Compuesto de amida, composicion farmaceutica que comprende el compuesto y uso de esta | |
| EP4595996A3 (en) | Treatment of lupus nephritis | |
| CO2023006028A2 (es) | Formulación combinada oral que incluye gemigliptina y dapagliflozina y método de preparación para la misma | |
| MX2024003930A (es) | Moduladores de trpml, sus composiciones y metodos de uso. |